# Philip Chamberlain

> Philip Chamberlain is the San Diego-based co-founder, president and CEO of Neomorph. An Oxford-trained structural biologist, he built a research department at Celgene before helping found Neomorph in 2020 and becoming CEO in November 2021. His career combines scientific research, team building and company leadership.

- **Role:** Co-founder, President and CEO at Neomorph, Inc.
- **Organizations:** Neomorph, Inc., Celgene, Bristol Myers Squibb, Genomics Institute of the Novartis Research Foundation, University of Oxford
- **Education:** BA, University of Oxford, DPhil; structural biology training, University of Oxford
- **Known for:** Built and led Celgene’s structural and chemical biology department., Received Celgene’s John W. Jackson leadership award., Contributed research on cereblon binding, neosubstrate recruitment and structural degrons.

## Career timeline

- **1999-2003** — Doctoral research at Oxford in David Stammers’s laboratory, as listed on his LinkedIn profile.
- **Before 2007** — Worked at the Genomics Institute of the Novartis Research Foundation in San Diego.
- **2007** — Joined Celgene; built and led its structural and chemical biology department.
- **2020** — Co-founded Neomorph and served as president and chief scientific officer.
- **2021-11-29** — Appointed CEO of Neomorph.
- **2026-04-13** — Neomorph announced a $100 million Series B led by Deerfield Management.

## Achievements

- Built and led Celgene’s structural and chemical biology department.
- Received Celgene’s John W. Jackson leadership award.
- Contributed research on cereblon binding, neosubstrate recruitment and structural degrons.
- Published work in Nature, Nature Structural and Molecular Biology, and Nature Chemical Biology.
- Co-founded Neomorph with Eric Fischer, Benjamin Ebert and Scott Armstrong.

## Latest updates

- **2026-05** — Neomorph appointed former Celgene chairman and CEO Robert J. Hugin as board chairman.
- **2026-05** — A published interview reported an 80,000-square-foot facility lease near Sorrento Mesa and a planned transition later in 2026.
- **2026-04** — Neomorph closed a $100 million Series B financing.

## Links

- Website: https://neomorph.com/team/philip-chamberlain-dphil/
- LinkedIn: https://www.linkedin.com/in/philip-chamberlain

---

Profile page: https://yespress.io/philip-chamberlain
Published by YesPress — https://yespress.io
Last updated: 2026-10-11